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Edited by Veli-Pekka LehtoAbstract Platelet activation by potent, Ca2+-mobilizing ago-
nists results in shedding of microparticles that are active in coag-
ulation. Here we show that platelets under storage produce
procoagulant microparticles in the absence of agonist. Micropar-
ticle formation by resting platelets results from aIIbb3 signaling
to destabilization of the actin cytoskeleton in the absence of cal-
pain activation. Integrin-mediated spreading of platelets over
ﬁbrinogen similarly results in microparticle formation. After
transfusion of stored platelet preparations to thrombocytopenic
patients, the microparticles contribute to coagulant activity
in vivo.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Platelets contribute to hemostasis and thrombosis by assem-
bling into aggregates and by stimulating blood coagulation. It
is generally assumed that, to become procoagulant, platelets
need to be stimulated with strong agonists, e.g. Ca2+ iono-
phore or the combination of collagen and thrombin [1,2]. In
a Ca2+-dependent response similar but non-identical to apop-
tosis, these agents cause surface exposure of negatively charged
phospholipids, such as phosphatidylserine (PS). This process
enhances the assembly of coagulation factor complexes, and
leads to the formation of factor Xa and thrombin and, hence,
to coagulation.
For over 20 years, it is known that the same strong agonists
also stimulate platelets to shed microparticles (MP), via Ca2+
inﬂux and activation of the Ca2+-dependent protease calpain,
which structures also express procoagulant PS at their outer
surface [3–6]. This shedding of MP, also described for other
cells of the cardiovascular system, is likely to be of physiolog-Abbreviations: FITC, Fluorescein isothiocyanate; mAb, monoclonal
antibody; MP, microparticles; PFP, platelet-free plasma; PRP, plate-
let-rich plasma; PS, phosphatidylserine
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doi:10.1016/j.febslet.2006.08.082ical relevance, as elevated MP levels in plasma associate with
cardiovascular disease and thrombotic complications [7,8].
The integrin aIIbb3 (>80000 copies per platelet) plays a well
established role in platelet aggregate and plug formation. It
signals in both directions over the plasma membrane. Follow-
ing platelet stimulation, signaling from the inside results in an
active integrin conformation, which is required for binding of
ﬁbrinogen and von Willebrand factor. In addition, once acti-
vated, the integrin transmits still poorly understood outside-
in signals in platelets, which include Src kinase and phospho-
inositide 3-kinase activity, and actin cytoskeleton modiﬁcation
via coﬁlin and ﬁlamin [9–12]. Integrin outside-in signaling is
known to mediate actin rearrangements that, for instance,
cause platelets to spread over an adhesive surface and to re-
tract, when encapsulated within a clot [13].
Preparations of platelets that are stored under blood bank
conditions and used for transfusion purposes appear to be en-
riched in MP with high coagulant activity [14]. How such MP
are formed by stored platelets has not been investigated. In the
present study, we show that resting platelets ‘spontaneously’
shed procoagulant MP via a mechanism that involves integrin
aIIbb3 signaling towards cytoskeleton remodeling, in the
apparent absence of integrin activation and platelet aggrega-
tion. This pathway diﬀers from that of agonist-induced MP
formation in the way that it does not require Ca2+ elevation
and calpain activity. The produced MP appear to be active
in coagulation, when transfused together with stored platelets
into thrombocytopenic patients.2. Materials and Methods
2.1. Materials
Abciximab (reopro) was from Centocor (Leiden, NL), tiroﬁban
(aggrastat) from Merck (Haarlem, NL), eptiﬁbatide (integrilin) and
lotraﬁban from GlaxoSmithKline (Zeist, NL), (labeled) annexin A5
from Nexins Research (Hoeven, NL) and iloprost from Schering (Ber-
lin, G). Fluorescein isothiocyanate (FITC)-labeled anti-P-selectin
monoclonal antibody (mAb) was from Immunotech (Marseille, F),
while FITC (PE)-anti-CD61 (anti-b3) mAb and isotype-matched
IgG1 were from BD Biosciences (San Jose, CA). Fura-2/AM, DM-
BAPTA1 AM and Alexa Fluor phalloidin were fromMolecular Probes
(Leiden, NL); jasplakinolide was from VWR (Amsterdam, NL). PP1-3
and calpeptin were from Calbiochem (San Diego, CA), cytochalasin D
and latrunculin B from Sigma (St. Louis, MO). The ﬂuorogenic cal-
pain substrate, tBoc-Leu-Met chloroamino methylcoumarin (tBoc-
LM-CMC), was from Invitrogen (Paisley, UK). Sources of other re-
agents are described elsewhere [15].blished by Elsevier B.V. All rights reserved.
5314 S. Cauwenberghs et al. / FEBS Letters 580 (2006) 5313–53202.2. Blood collection and platelet preparation
Blood was drawn after full consent by venapuncture from healthy
volunteers, free of medication [16]. Blood was also obtained from a
thrombocytopenic patient with myeloproliferative disorder both be-
fore and shortly after platelet transfusion [17]. Experiments were ap-
proved by the local Medical Ethics Committee. Platelet-rich plasma
(PRP) was collected by centrifuging blood at 240 · g for 15 min; leuko-
cyte count was <1 · 103/ml. Washed platelets were prepared from PRP
[16], and resuspended at 4 · 108 platelets/ml in HEPES buﬀer, pH 7.45
(136 mM NaCl, 10 mM HEPES, 2.7 mM KCl, 2 mM MgCl2, 0.1%
bovine serum albumin and 0.1% glucose).
2.3. Platelet incubation and aggregation
PRP or washed platelets, normalized at 4 · 108 platelets/ml, were
slowly rotated (10 rpm) at room temperature in closed, air-transparent
tubes for up to 24 h. Inhibiting or activating agents were added, as de-
scribed. At indicated times, MP-containing platelet-free plasma (PFP)0
100
200
300
400
0 50 100 150
0
5000
10000
15000
20000
25000
SS
 lo
g
FS log
time (min)
th
ro
m
bi
n 
in
 P
RP
 (n
M)
0h
3h
6h
24h
de
te
ct
ed
 M
P/
µl
0h 6h 0h 6hmax max
PRP washed plts
B
A
+ anx A5
C
** *
104
103
102
101
100
100 101 102 103 104
Fig. 1. Progressive shedding of procoagulant MP during platelet storage. (
incubated at room temperature under rotation for 0-24 h. Right: Tissue facto
rotated PRP. Annexin A5 (10 lg/ml) was added at 5 min before tissue facto
cytometric detection of MP in 6-h rotated PRP. Co-labeling with FITC-an
cytometric measurement of MP in PRP and in washed platelet suspension,
stimulation with 50 ng/ml convulxin and 20 lM ADP (PRP), or with 10 lM
by ﬂow cytometry and MP-derived thrombin generation in plasma (R2 =
**P < 0.05, compared to 0 h.was obtained by centrifuging 0.5 ml samples of the PRP at 20000 · g
for 10 min. Platelet count in the PFP was below detection (<1 · 105/
ml), while loss of MP was about 20%.
Aggregation of platelets in PRP was determined under stirring at
37 C by conventional aggregometry [18]. Citrate-anticoagulated
PRP was recalciﬁed with 16.6 mM CaCl2 in the presence of Phe-Pro-
Arg chloromethyl ketone (PPACK, 10 lM), to achieve mM concentra-
tions of free Ca2+ and Mg2+ without coagulation [15].
2.4. Flow cytometry
Platelet activation was measured by ﬂow cytometry, using FITC-
labeled mAbs against P-selectin or activated aIIbb3 (PAC1) [14]. FITC-
annexinA5wasused to detect exposedPS. Platelet-derivedMP in plasma
were measured after dilutionwith anticoagulated, ﬁlteredHEPES buﬀer,
pH 7.45. After 15 min labeling with PE-anti-b3 mAb, the MP were de-
tected as ﬂuorescent events with low forward and side scatter positively
staining for aIIbb3. Fluorescent beads were used for calibration.0
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A) Left: Tissue factor-induced thrombin generation of PRP that was
r-induced thrombin generation of PFP prepared by centrifuging of the
r, where indicated (6 h rotation, curves coincide with x-axis). (B) Flow
nexin A5 (FL1) and PE-labeled anti-b3 mAb (FL2). (C) Left: Flow
incubated for 0–6 h. Maximal (max) amounts of MP were formed by
ionomycin (washed platelets). Right: Correlation between MP detected
0.97, P = 0.013). Data are means ± S.E.M. (n = 3–5), *P < 0.1 and
S. Cauwenberghs et al. / FEBS Letters 580 (2006) 5313–5320 53152.5. Measurement of thrombin generation in plasma
Platelet-dependent thrombin generation was measured in PRP [19].
Assay conditions were 1 · 108 platelets/ml, 67% citrate plasma and
33% buﬀer A (140 mM NaCl, 20 mM HEPES, 0.5% bovine serum
albumin, pH 7.45). Reactions were started by addition of 1 pM (f.c.)
tissue factor, 16.6 mM CaCl2 and 415 lM ﬂuorescent substrate Z-
Gly-Gly-Arg aminomethyl coumarin. Similar reaction conditions were
used to measure MP-dependent thrombin generation, but now using
centrifuged (MP-containing) PFP. Assays were performed in triplicate
at 37 C using a Fluoroskan Ascent well plate reader [19]. Controls
were always run to exclude interference of (ant)agonists with the coag-
ulation process per se.
2.6. Real-time measurement of calpain activity
PRP, incubated for up to 24 h at room temperature, was used to pre-
pare washed platelets in the presence of apyrase [15]. The washed cells
were treated with vehicle of calpeptin (140 lM), and loaded with the
ﬂuorogenic calpain substrate, tBoc-LM-CMC, for 30 min at 37 C,
as described [20]. During the measurements, EGTA (1 mM) was added
to prevent possible extracellular calpain activity. Intracellular calpain
activity was measured from ﬂuorescence increases due to substrate
cleavage by stopped-ﬂow ﬂuorometry (agonists present as shown)
[20]. Fluorescence increase in time was corrected for probe autoﬂuores-
cence at baseline; averaged traces were produced from three repeated
scans.2.7. Microscopy
Phase-contrast and (confocal) ﬂuorescence microscopy were per-
formed as described [21].2.8. Statistical analysis
Signiﬁcance of diﬀerences was determined with the non-parametric
Mann–Whitney U test. A
B
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Fig. 2. Minimal activation state of MP-forming platelets. (A) Flow
cytometric detection of activation markers on platelets, incubated in
plasma for 6 h. Platelets expressing P-selectin, activated integrin
aIIbb3 (PAC1) or PS (Anx A5) after incubation in plasma for 0–6 h.
Platelets were maximally activated (max), as described for Fig. 1. (B)
Representative aggregation traces of PRP stimulated with ADP
(10 lM) or collagen (2.5 lg/ml) after 6 h incubation. Data are
means ± S.E.M. (n = 3). *P < 0.1 and **P < 0.05 compared to 0 h.3. Results
3.1. Platelets shed procoagulant MP at minimal activation
Triggering of freshly isolated PRP with tissue factor gives a
delayed generation of thrombin [19,22]. Experiments indicated
that, when platelets in plasma were incubated under slow rota-
tion at room temperature for up to 24 h (conditions resembling
those of platelet storage), the rate and extent of tissue factor-
triggered thrombin generation greatly increased with the time
of incubation (Fig. 1A). To determine the contribution of
MP in the increased coagulant activity, incubated PRP sam-
ples were centrifuged at a high speed removing all platelets.
The supernatant PFP was also increasingly active in thrombin
formation (maximal levels 25–250 nM), after triggering with
tissue factor (Fig. 1A). Control experiments showed that
10 lg/ml of PS-blocking annexin A5 completely inhibited
thrombin generation, in both the incubated PRP and the cen-
trifuged PFP samples (Fig. 1A). This indicated that all throm-
bin generation in plasma relied on the presence of
procoagulant PS.
Flow cytometry was used to conﬁrm the formation of MP in
the rotated PRP. The MP were identiﬁed as small-size scatter
events, staining positive for integrin b3. Double-staining indi-
cated that most of the b3-positive events also stained with ﬂuo-
rescent-labeled annexin A5, pointing to exposed PS (Fig. 1B).
Prolonged, 6-h incubation of PRP resulted in a progressive
accumulation of the MP, although their level remained lower
than that of platelets stimulated with strong agonists
(Fig. 1C, left). Interestingly, MP formation was also detected
in suspensions of washed platelets that were long incubated
in HEPES buﬀer under rotation. Thrombin generation mea-surements showed a high correlation between the MP levels,
detected by ﬂow cytometry, and the coagulant activity of the
centrifuged PFP samples (Fig. 1C, right). As required, ultra-
speed centrifugation of the PFP, to pellet all MP, resulted in
completely abolished thrombin generation. Together, these
data indicate that prolonged incubation of platelets in either
plasma or buﬀer leads to shedding of MP with high thrombo-
genic activity.
To investigate how MP shedding inﬂuenced the function of
platelets, we performed ﬂow cytometric measurements of
platelet activation markers. After 6-h incubation of PRP, only
5–8% of the platelets expressed P-selectin (a marker of exocy-
tosis), activated aIIbb3 integrin (detected with FITC-PAC1
mAb), or PS (Fig. 2A). This sharply contrasted the 100%
of platelets expressing these activation markers after stimula-
tion with the strong agonists convulxin/ADP or ionomycin.
Furthermore, the incubated PRP still had high aggregation re-
sponses with lower doses of ADP or collagen (Fig. 2B). It thus
appears that the shedding of procoagulant MP is accompanied
by minimal platelet activation, and is of little inﬂuence on ago-
nist-induced platelet aggregation.
3.2. ‘Spontaneous’ MP formation is mostly independent of
calpain but is controlled by aIIbb3
Early reports indicate that strong platelet agonists activate
the Ca2+-dependent protease, calpain, which then plays a
5316 S. Cauwenberghs et al. / FEBS Letters 580 (2006) 5313–5320regulatory role in MP formation [6,23]. We determined that
levels of cytosolic Ca2+ concentration in the platelets remained
low during a 24-h incubation, i.e. changing from 26 ± 0.8 to
only 29 ± 4 nM. Subsequently, we measured intracellular cal-
pain activity before and after incubation of the platelets, using
a newly developed procedure. Therefore, (incubated) platelets
were loaded with the speciﬁc calpain substrate, tBoc-LM-
CMC, and ﬂuorescence development due to intracellular sub-
strate cleavage was followed by stopped-ﬂow ﬂuorometry in
the presence of EGTA to prevent contribution of possibly
leaked calpain [20]. In agreement with earlier results [20], the
Ca2+-mobilizing agent, thapsigargin, caused an increase in ba-
sal calpain activity (Fig. 3A). In contrast, platelet incubation
for 24 h resulted in a 33% decrease in calpain activity. As re-
quired, pretreatment of the platelets with the speciﬁc calpain
inhibitor, calpeptin, abolished ﬂuorescence development.
To determine whether the low calpain activity of resting
platelets contributed to MP formation, PRP was incubated
with calpeptin, and then evaluated on presence of coagulant
MP. Calpeptin addition led to only a small, 35% reduction
in the MP activity (Fig. 3B), indicating that the contribution
of calpain-mediated protein cleavage in MP shedding is re-
stricted.
Plasma contains ADP-degrading proteins that antagonize
the eﬀects of autocrine released ADP [15]. Yet, to determine0
50
100
150
0
50
100
150
1
1
m
ic
ro
pa
rti
cle
 a
ct
ivi
ty
 (%
)
m
ic
ro
pa
rti
cle
 a
ct
ivi
ty
 (%
)
ca
lpe
pti
n
**
tB
oc
-L
M
-C
M
C 
flu
or
es
ce
nc
e 
(%
)
0h
ca
lpe
pti
n
24
h
B
A
**
**
DM
-
BA
PT
A
tha
ps
iga
rgi
n
**
Fig. 3. Involvement of calpain and autocrine mediators in shedding of coagu
was loaded with tBoc-LM-CMC, and intracellular calpain activity was ass
Samples were pre-treated with calpain inhibitor, calpeptin (140 lM), or acti
percentages of 0-h control. (B) MP coagulant activity. PRP was incubated
(10 lM) or a mixture of MRS2179 (20 lM), AR-C66931MX (30 lM), apyra
eﬀects. Platelets were preloaded with DM-BAPTA1, where indicated. Data a
Means ± S.E.M. (n = 5, *P < 0.1 and **P < 0.05 vs. control).the possible involvement of autocrine mediators, PRP was ro-
tated in the presence of a cocktail of inhibitors of the ADP and
thromboxane A2 pathways [21]. This treatment had a small,
about 30% reducing eﬀect on the formation of coagulant MP
(Fig. 3B). Treatment of PRP with the cAMP-elevating com-
pound, iloprost, at concentrations giving a 3–4-fold increase
in cytosolic cAMP, resulted in an about 65% suppression of
MP formation (Fig. 3B). Control experiments further showed
that this MP formation was not due to incomplete anti-coagu-
lation, because the level of thrombin–antithrombin complexes
remained far below threshold levels of coagulation initiation
(<3 ng/ml) after 6 h or even 5 days of incubation of the PRP.
To study the involvement of aIIbb3, the PRP was incubated
with various clinically used blockers of this integrin: the high-
aﬃnity chimeric antibody, abciximab, a KGD-based peptide,
eptiﬁbatide, and the non-peptide antagonists, tiroﬁban and
lotraﬁban [24]. These antagonists potently decreased MP for-
mation in 6-h incubated PRP with 65–80%, as determined
from their coagulant activity (Fig. 4A). Also ﬂow cytometry
indicated that tiroﬁban reduced the number of MP in plasma
with 87 ± 5% (n = 7). Further experiments showed that tiroﬁ-
ban inhibited thrombin generation, only when added to PRP
before the 6-h incubation time (Fig. 4B). In contrast, tiroﬁ-
ban was without eﬀect on coagulation when post-added to
MP-containing PRP (Fig. 4C) or to PFP (not shown). These0
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Fig. 4. Involvement of integrin aIIbb3 in spontaneous MP formation.
PRP was incubated for 6 h with or without aIIbb3 inhibitors,
abciximab (20 lg/ml), tiroﬁban (2 lM), lotraﬁban (20 lM) or eptiﬁ-
batide (6 lM). (A) Coagulant activity of MP in plasma (PFP) after 6 h
of incubation. (B) Eﬀect of tiroﬁban added to fresh PRP. (C) Eﬀect of
tiroﬁban added after incubation of PRP for 6 h. Shown are represen-
tative thrombin generation curves. Data are expressed as percentages
of control PRP (6-h incubation without inhibitors), and are
means ± S.E.M. (n = 4, **P < 0.05).
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Fig. 5. Involvement of actin cytoskeleton in MP formation. (A) PRP
was incubated for 6 h with/without cytochalasin D (10 lM), latruncu-
lin B (0.5 lM) or jasplakinolide (10 lM). (B) PRP was incubated for
6 h with cytochalasin D in the presence of integrin blockers (ﬁg. 4). (C)
PRP was incubated with cytochalasin D plus wortmannin (1 lM).
Data indicate MP coagulant activity as percentages of control PRP
(incubation without drugs). **P < 0.05 vs. control PRP,**P < 0.05 vs.
vehicle (n = 3–4).
S. Cauwenberghs et al. / FEBS Letters 580 (2006) 5313–5320 5317ﬁndings suggest that the anticoagulant eﬀect of integrin block-
ers is through inhibition of MP formation, and not by directly
interfering with the thrombin generation process.
3.3. Involvement of aIIbb3-mediated actin cytoskeleton turnover
and outside-in signaling
As the actin cytoskeleton is of key importance for platelet
structural integrity, we examined how compounds interfering
with actin ﬁlament turnover inﬂuenced the shedding of MP.
Platelets in plasma were incubated with cytochalasin D, an
agent that caps actin ﬁlaments and prevents their polymeriza-
tion [25]. Remarkably, this resulted in a potent, twofold in-
creased formation of procoagulant MP (Fig. 5A). A similar,
stimulating eﬀect was obtained, when platelets were incubated
with latrunculin B, which inhibits ﬁlament polymerization by
binding to actin monomers; or with jasplakinolide, whichfreezes platelet actin ﬁlaments but does allow severing [26].
All compounds rearranged actin to a layer close to the plasma
membrane, as was conﬁrmed by staining of the platelets with
ﬂuorescent phalloidin.
Interestingly, the enhancing eﬀects of cytochalasin D and
jasplakinolide on MP shedding were reversed by integrin
blockade with abciximab or tiroﬁban (Fig. 5B). This led to
the suggestion that aIIbb3 activity causes MP formation via
destabilization of the actin cytoskeleton. The involvement of
Src kinase and phosphoinositide 3-kinase was then considered,
5318 S. Cauwenberghs et al. / FEBS Letters 580 (2006) 5313–5320which protein kinases have been implicated in signaling of
aIIbb3 to cytoskeletal changes [11]. Incubation of PRP with
the 3-kinase inhibitor wortmannin halved MP formation,
and also reversed the enhancing eﬀect of cytochalasin D
(Fig. 5C). Inhibition of Src kinases with 20 lM PP1 or PP2
(but not the control substance PP3) reduced microvesiculation
by 39 ± 7% (n = 5, P < 0.01).
The cytochalasin D-enhanced and tiroﬁban-suppressed MP
formation did not involve calpain activity, as calpeptin
(140 lM) treatment was without inﬂuence on this process. Fur-
thermore, platelet treatment with cytochalasin D or tiroﬁban
changed the intracellular calpain activity insigniﬁcantly with
4% and 7 ± 3%.
Although the aIIbb3 activation state of platelets in plasma
in general is low (compare Fig. 2A), the above results suggestFig. 6. MP formation of spreading platelets. Platelets in HEPES buﬀer
were immobilized on a ﬁbrinogen surface for 45 min at room
temperature. (A) Representative phase-contrast image of spreading
platelets with MP (arrows). (B) Microscopic images of actin staining
with AF-phalloidin, and of PS exposure with OG-annexin A5. (C)
Dual confocal staining of MP-forming platelets with AF-annexin A5
and FITC-anti b3. Bars represent 5 lm.that a low, residual integrin activity is suﬃcient to cause MP
formation. Support for this came from ﬂow-cytometric mea-
surements, showing that PAC1 binding to platelets stored in
plasma was slightly above basal; the mean PAC1 binding re-
duced with 3 channel numbers by treatment of the platelets
with cAMP-elevating iloprost.
The spreading of platelets over a ﬁbrinogen surface is an
event controlled by integrin outside-in signaling [27]. We inves-
tigated whether this signaling during spreading also leads to
MP formation. High-resolution, phase-contrast microscopy
showed that many platelets, in a late stage of spreading, often
developed circular arrays of cell-attached MP after forming
lamellipods (Fig. 6A, see also movie A). Confocal ﬂuorescence
microscopy indicated that these MP express PS and form at
sites of disintegrated actin ﬁlaments (Fig. 6B). Dual labeling
demonstrated PAC1 staining of the PS-positive MP
(Fig. 6C). Control experiments conﬁrmed that integrin block-
ers antagonized both the spreading and MP formation.
Finally, thrombin generation experiments were performed
with PRP from thrombocytopenic patients, who were trans-
fused with MP-containing platelet preparations stored at
blood bank conditions. After transfusion, the thrombin peak
level in both PRP and PFP was notably increased, pointing
to the presence of circulating MP in the patient blood
(Fig. 7). Thus, MP produced during platelet storage actively
contribute to the coagulation process, when transfused into
patients.4. Discussion
This report describes the novel ﬁnding that human platelets
during storage form procoagulant MP as a ‘spontaneous’ reac-
tion, in a way dependent on integrin aIIbb3 and cytoskeleton
turnover, but at minimal platelet activation and calpain activ-
ity. This process is of clinical relevance, since MP-producing
platelet preparations are routinely transfused to patients, and
can enhance coagulation.
Flow cytometry was used to detect the gradual accumulation
of MP in stored platelets. Complementary to this, thrombin
generation measurements allowed quantiﬁcation of the
amounts of procoagulant MP in plasma. We ﬁnd that the
spontaneous MP formation is an ongoing process in platelets,
which relies on integrin signaling even when platelet activation
is minimal. Only a minority of the MP-producing platelets
bound PAC1 mAb, or had signs of surface expression of P-
selectin or PS. Furthermore, the aggregation tendency of
MP-producing platelets was no more than slightly altered.
The results do not indicate whether MP are produced by a
small fraction of the platelets or by all platelets. In favor of
the latter possibility is the overall decrease in mean platelet vol-
ume of about 10%, which is detectable after prolonged incuba-
tion.
The mechanism of MP shedding from resting platelets, typ-
ically, diﬀers from the shedding mechanism that is described
for platelets treated with potent agonists like Ca2+-ionophore
or collagen/thrombin. In these cases, it has been shown that
basal calpain activity is insuﬃcient for its protease activity to
degrade cytoskeletal components, and that agonist-induced
Ca2+ inﬂux is required to reach the high, (sub)micromolar
[Ca2+]i levels triggering this protease activity. Similarly, with
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Fig. 7. Thrombin generation of PRP and PFP from a thrombocytopenic patient before and after transfusion with a platelet-plasma preparation.
Platelet counts in patient PRP before and after transfusion were 16 and 64 · 109/l, respectively. PRP and PFP samples pre- and post-perfusion were
triggered with tissue factor, as described for Fig. 1A. Also shown is thrombin generation of the PRP and plasma that was used for transfusion.
Increased thrombin generation in post-transfusion PFP points to activity of coagulant MP. Representative thrombin generation curves are given
(triplicate assays).
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calpain dependent MP formation [5,6,12,23,28]. In contrast, in
the present setting, we ﬁnd that Ca2+ levels remain low in the
stored platelets (with low extracellular Ca2+ in the storage
medium), while the basal calpain activity even decreases. Fur-
thermore, we ﬁnd that Ca2+ chelation and calpain inhibition
have only minor eﬀects on MP formation. Together, this indi-
cates that the Ca2+/calpain pathway plays only a minor role in
MP shedding during platelet storage.
We ﬁnd that integrin aIIbb3 plays an important role in the
shedding process of resting platelets. Some authors have re-
ported that aIIbb3 activation and aggregation are also in-
volved in MP production by platelets stimulated with potent
agonists [12,29], while others have not found such involvement
of the integrin [30,31]. In activated platelets, aIIbb3 can fur-
thermore regulate calpain activation [32]. Based on these and
other ﬁndings, Fox [6] and Wiedmer [28] and colleagues have
suggested that there may be more than one mechanism of
MP formation. Taken together with the present results, we
conclude that there must be a separation between the Ca2+/cal-
pain and the aIIbb3 pathways, although both may operate
alongside each other or synergize. Mostly the aIIbb3-medi-
ated, calpain-independent pathway is then responsible for
MP formation by stored platelets.
There is recent evidence to indicate that integrins on a cell
surface are in constitutive equilibrium between inactive and ac-
tive conformations [33]. This raises the possibility that patches
of active (signaling) integrins on otherwise unstimulated plate-
lets can trigger local shedding of MP. This would also explain
why inhibition of Src or phosphoinositide 3-kinase signaling
suppresses MP formation, likely via interference in outside-in
signaling. However, it should be noted that, in stimulated
platelets, these protein kinases also contribute to inside-out
signaling [34].
A remarkable ﬁnding is that the aIIbb3-mediated MP for-
mation increases with compounds like cytochalasin D, inter-
fering with the actin cytoskeleton turnover. It is known that
actin-binding proteins, such as ﬁlamin and coﬁlin, provide
physical interaction of the cytoskeleton with the b3 cytoplas-
mic tail of integrin aIIbb3 [25]. Particularly, the phosphoinosi-
tide 3-kinase signaling pathway links between aIIbb3 and actin
dynamics [11]. This leads to the idea that integrin signaling via
this pathway locally destabilizes the cytoskeleton (via coﬁlin),
with as a result disconnection of the plasma membrane and
shedding of MP. Support for such a mechanism comes fromthe hitherto unrecognized detection of MP at the edges of
platelets spread on ﬁbrinogen and the observed eﬀect of Src ki-
nase inhibitors. Thus, activated integrins may act by suppres-
sion of the (spontaneous) rearrangement of the actin
cytoskeleton and, conversely, cytoskeleton turnover suppresses
integrin activation and hence MP formation.
Integrin blockers have a clinically relevant, anticoagulant ef-
fect in the circulation by suppressing the availability of proco-
agulant lipid surface [35]. The present ﬁndings indicate that
this anti-integrin eﬀect particularly relies on inhibition of MP
formation. We can thus conclude that integrin-mediated shed-
ding of MP is a uniquely regulated cellular response that con-
tributes to coagulant activity in a clinically relevant way.
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